WLLW — Willow Biosciences Income Statement
0.000.00%
Last trade - 00:00- CA$5.07m
- CA$5.63m
- CA$4.66m
Annual income statement for Willow Biosciences, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.01 | 0.133 | 0.821 | 1.17 | 4.66 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 34 | 23.5 | 19.6 | 14.4 | 10.1 |
| Operating Profit | -33.9 | -23.3 | -18.8 | -13.2 | -5.45 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -33.9 | -6.14 | -14.8 | -13 | -6.19 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -33.9 | -6.14 | -14.8 | -13 | -6.19 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -33.9 | -6.14 | -14.8 | -13 | -6.19 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -33.9 | -6.14 | -14.8 | -13 | -6.19 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.338 | -0.05 | -0.118 | -0.105 | -0.047 |